Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran
- PMID: 34001057
- PMCID: PMC8127291
- DOI: 10.1186/s12889-021-10511-7
Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran
Abstract
Background and objectives: Sarcopenia is an important age-related disease which can lead to an increased risk of mortality, falls, fractures, and poor quality of life. So, timely detection can be effective in reducing the burden of disease. The aim of this study was to identify the most cost-effective strategy for sarcopenia screening in Iran.
Materials and methods: We constructed a Markov transition model over a life-time horizon based on natural history. Compared strategies included Sarcopenia scoring assessment models (SarSA-Mod), European working group on sarcopenia in older people (EWGSOP), Mini sarcopenia risk assessment (MSRA) and SARC-F. Parameters values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Sensitivity analysis of uncertain parameters was also performed to determine the robustness of the model. Analysis was performed using 2020 version of TreeAge Pro software.
Results: All four screening strategies increased life time QALYs. After removing dominated strategy, the incremental cost per QALY gained for sarcopenia screening varied from $1875.67 for EWGSOP to $1898.33 for MSRA. Our base-case analysis showed that the most cost-effective strategy was EWGSOP and 2nd best was SarSA-Mod with $43,414.3 and $42,663.3 net monetary benefits given one GDP per capita ($5520.311) as willingness to pay, respectively. Sensitivity analysis of model parameters also showed robustness of results.
Conclusions: The results of the study, as the first economic evaluation of sarcopenia screening, showed that the EWGSOP strategy is more cost-effective than other strategies.
Keywords: Cost effectiveness analysis (CEA); QALY; Sarcopenia; Screening.
Conflict of interest statement
There are no conflicts of interest that are directly relevant to the content of this article.
Figures






Similar articles
-
Cost-effectiveness analysis of sarcopenia management interventions in Iran.BMC Public Health. 2023 May 4;23(1):819. doi: 10.1186/s12889-023-15693-w. BMC Public Health. 2023. PMID: 37143011 Free PMC article.
-
Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.Helicobacter. 2023 Dec;28(6):e13027. doi: 10.1111/hel.13027. Epub 2023 Oct 15. Helicobacter. 2023. PMID: 37839058
-
Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population.Arch Iran Med. 2017 Sep;20(9):564-571. Arch Iran Med. 2017. PMID: 29048918
-
The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia.Gerontology. 2017;63(5):411-416. doi: 10.1159/000477935. Epub 2017 Jul 5. Gerontology. 2017. PMID: 28675898
-
The cost-effectiveness of screening for oral cancer in primary care.Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv. doi: 10.3310/hta10140. Health Technol Assess. 2006. PMID: 16707071 Review.
Cited by
-
Ethical considerations in sarcopenia research.J Med Ethics Hist Med. 2023 Dec 2;16:8. doi: 10.18502/jmehm.v16i8.14303. eCollection 2023. J Med Ethics Hist Med. 2023. PMID: 38260766 Free PMC article. No abstract available.
-
Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease.Int J Nurs Sci. 2023 Dec 31;11(1):3-10. doi: 10.1016/j.ijnss.2023.12.014. eCollection 2024 Jan. Int J Nurs Sci. 2023. PMID: 38352295 Free PMC article.
-
South Asian Working Action Group on SARCOpenia (SWAG-SARCO) - A consensus document.Osteoporos Sarcopenia. 2022 Jun;8(2):35-57. doi: 10.1016/j.afos.2022.04.001. Epub 2022 May 25. Osteoporos Sarcopenia. 2022. PMID: 35832416 Free PMC article. Review.
-
Muscle elasticity variations in assessing age-related changes in adults - A systematic review.Geriatr Gerontol Int. 2025 Jul;25(7):855-863. doi: 10.1111/ggi.70073. Epub 2025 Jun 11. Geriatr Gerontol Int. 2025. PMID: 40500788 Free PMC article. Review.
-
The effect of Sarcomeal® oral supplementation plus vitamin D3 on muscle parameters and metabolic factors in diabetic sarcopenia patients: study protocol of a randomized controlled clinical trial.Trials. 2024 Dec 23;25(1):848. doi: 10.1186/s13063-024-08700-x. Trials. 2024. PMID: 39716287 Free PMC article.
References
-
- As’ habi A, Najafi I, Tabibi H, Hedayati M. Prevalence of sarcopenia and dynapenia and their determinants in Iranian peritoneal dialysis patients. Iranian J Kidney Dis. 2018;12(1):53. - PubMed
-
- Heshmat R, Shafiee G, Shadman Z, Hashemi R, Khatami F, Ahadi Z, et al. A comprehensive manual on sarcopenia. 1. Noavaran Sina: Tehran; 2017.
-
- Narici MV, Reeves ND, Morse CI, Maganaris CN. Muscular adaptations to resistance exercise in the elderly. J Musculoskelet Nueronal Interact. 2004;4(2):161–164. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources